XNAS
WGS
Market cap2.06bUSD
Jul 09, Last price
69.39USD
1D
5.75%
1Q
16.39%
IPO
-78.54%
Name
GeneDx Holdings Corp
Chart & Performance
P/E
—
P/S
4.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
36.73%
Rev. gr., 5y
18.98%
Revenues
428m
+39.97%
Net income
-21m
L-59.80%
CFO
33m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CM Life Sciences, Inc., established in 2020 and based in New York, New York, plans to pursue various strategic business combinations. These initiatives may involve mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar consolidations with one or more enterprises.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||